Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Mantle-Cell 9Lymphoma, B-Cell, Marginal Zone 4Waldenstrom Macroglobulinemia 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia, B-Cell 2Leukemia 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 29Prednisone 27Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × pirtobrutinib × Clear all
NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

NCT06812715 2025-08-06

PIPOZA

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡